<DOC>
	<DOCNO>NCT00276835</DOCNO>
	<brief_summary>RATIONALE : Genistein may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Interleukin-2 may stimulate white blood cell , include natural killer cell , kill melanoma kidney cancer cell . Giving genistein together interleukin-2 may kill tumor cell . PURPOSE : This phase II trial study well give genistein together interleukin-2 work treat patient metastatic melanoma kidney cancer .</brief_summary>
	<brief_title>Genistein Interleukin-2 Treating Patients With Metastatic Melanoma Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Measure differences peak duration expansion circulate CD4-positive , CD8-positive , CD4- , CD25- , CD56-positive cell ( dim bright ) different time point therapy interleukin-2 ( IL-2 ) alone plus genistein patient metastatic malignant melanoma renal clear cell carcinoma . Secondary - Evaluate difference peripheral blood mononuclear cell gene expression follow high-dose IL-2 without genistein compare baseline . - Determine overall response rate ( partial complete ) patient treat regimen . - Determine safety toxic effect regimens patient . - Determine time progression patient treat regimen . OUTLINE : This pilot study . Patients receive high-dose interleukin-2 IV 15 minute twice daily day 1 15 3 time daily day 2-5 16-19 . Patients also receive oral genistein twice daily day 10-19 . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 15 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Genistein</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Documented histologically confirm malignant melanoma renal clear cell carcinoma Metastatic disease At least 1 measurable lesion accurately measure least one dimension long diameter &gt; 20 mm use conventional technique OR &gt; 10 mm spiral CT scan If measurable disease restrict solitary lesion , neoplastic nature confirm cytology/histology Clinical lesion consider measurable superficial ( e.g. , skin nodule palpable lymph node ) The following consider nonmeasurable lesion : Bone lesion Leptomeningeal disease Ascites Pleural/pericardial effusion Inflammatory breast disease Lymphangitis cutis/pulmonis Cystic lesion Abdominal mass confirm followed imaging technique No CNS metastases CT scan MRI PATIENT CHARACTERISTICS : ECOG performance status &lt; 2 Life expectancy ≥ 4 month Serum creatinine &lt; 2.0 mg/dL OR creatinine clearance &gt; 50 mL/min Bilirubin normal Platelets &gt; 100,000/mm³ WBC &gt; 3,500/mm³ No evidence congestive heart failure No symptom coronary artery disease No serious cardiac arrhythmia A pretreatment cardiac stress test must perform within 42 day IL2 treatment cardiac symptom present ( patient document ischemia pretreatment cardiac stress test exclude study ) Adequate pulmonary reserve FEV_1 &gt; 75 % predict Not pregnant nursing Fertile patient must use effective contraception Negative pregnancy test No known HIVpositive patient No evidence active infection require antibiotic therapy No contraindication treatment pressor agents No significant medical disease , opinion investigator , may interfere completion study No history another malignancy basal cell skin cancer within 5 year PRIOR CONCURRENT THERAPY : Recovered toxic effect prior therapy No radiotherapy , chemotherapy , immunotherapy 4 week prior first dose study treatment No systemic corticosteroid 4 week prior treatment No previous investigational agent within 4 week prior start study No prior interleukin2 therapy No organ allograft allow No concurrent radiotherapy , chemotherapy , immunotherapy No concurrent corticosteroids No concurrent chronic medication asthma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>clear cell renal cell carcinoma</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
</DOC>